NexImmune (NEXI) has released an update to notify the public and investors about an entry into a material definitive agreement.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
NexImmune, Inc. has struck a deal with a healthcare-focused institutional investor to sell over 117,000 shares and pre-funded warrants in a registered direct offering, with expectations to raise approximately $3.67 million before fees and costs. Additionally, in a private placement, they will issue unregistered warrants for more shares. These transactions are part of an offering under a previously filed SEC registration statement. The company also has an agreement with H.C. Wainwright & Co. for placement agent services, promising them fees and warrants as compensation. The offerings are contingent on standard closing conditions and do not yet have an established trading market for the unregistered warrants.
For further insights into NEXI stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
